Bio-Techne Expands GMP Manufacturing with New Bristol Facility
Event summary
- Bio-Techne opened a 10,000-square-foot GMP manufacturing facility in Bristol, UK, featuring five ISO-8 and two ISO-7 cleanrooms for small molecule production.
- The facility complements Bio-Techne's existing GMP capabilities in Minneapolis, St. Paul, and its partnership with Wilson Wolf Corporation.
- The investment aims to address scalability challenges in the rapidly growing cell therapy market.
- Bio-Techne generated over $1.2 billion in net sales in fiscal year 2025.
The big picture
Bio-Techne's new Bristol facility strengthens its position as a key player in the cell therapy manufacturing space, addressing industry-wide challenges in scalability and reproducibility. The expansion aligns with broader trends in the biotech sector, where manufacturing infrastructure is critical for accelerating the development and commercialization of advanced therapies. With over $1.2 billion in annual revenue, Bio-Techne is well-positioned to capitalize on the growing demand for high-quality GMP materials and manufacturing expertise.
What we're watching
- Market Demand
- How the growing cell therapy market will drive utilization of Bio-Techne's expanded GMP capacity.
- Competitive Positioning
- Whether Bio-Techne can sustain its lead in GMP manufacturing services amid increasing competition.
- Regulatory Compliance
- The pace at which evolving regulatory expectations will impact Bio-Techne's manufacturing standards.
Related topics
